• Je něco špatně v tomto záznamu ?

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

G. Schernthaner, H. Drexel, E. Moshkovich, B. Zilaitiene, E. Martinka, L. Czupryniak, T. Várkonyi, A. Janež, K. Ducena, K. Lalić, T. Tankova, M. Prázný, L. Smirčić Duvnjak, O. Sukhareva, H. Sourij,

. 2019 ; 19 (1) : 64. [pub] 20190617

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044750

BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. EXPERT OPINION: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. CONCLUSION: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.

1st Dept of Internal Medicine University of Szeged Szeged Hungary

Clinic for Endocrinology Diabetes and Metabolic Diseases Clinical Centre of Serbia Faculty of Medicine University of Belgrade Beograd Serbia

Clinical Centre of Endocrinology Medical University Sofia Sofia Bulgaria

Department of Diabetology and Internal Medicine Warsaw Medical University Warsaw Poland

Department of Endocrinology Diabetes and Metabolic Diseases University Medical Centre Ljubljana Slovenia

Department of Medicine 1 Rudolfstitung Hospital Vienna Austria

Diabetes Centre Charles University and General Faculty Hospital Prague Czech Republic

Division of Endocrinology and Diabetology Medical University of Graz Graz Austria

Division of Endocrinology Faculty of Internal Medicine University of Latvia Riga Latvia

Endocrinology Research Centre Moscow Russian Federation

Institute of Endocrinology Lithuanian University of Health Sciences Kaunas Lithuania

National Institute of Endocrinology and Diabetology Lubochna Slovakia

School of Medicine University of Zagreb Vuk Vrhovac University Clinic UH Merkur Zagreb Croatia

Unit of Endocrinology and Metabolism Sapir Medical Center Kfar Saba Israel

VIVIT Institute Academic Teaching Hospital Feldkirch Feldkirch Austria Vorarlberg Institute for Vascular Investigation and Treatment Feldkirch Austria Division of Angiology Swiss Cardiovascular Center University Hospital of Berne Bern Switzerland Private University of the Principality of Liechtenstein Triesen Liechtenstein Drexel University College of Medicine Philadelphia PA USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044750
003      
CZ-PrNML
005      
20200113101306.0
007      
ta
008      
200109s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12902-019-0387-y $2 doi
035    __
$a (PubMed)31208401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Schernthaner, Guntram $u Department of Medicine I, Rudolfstitung Hospital, Vienna, Austria. guntram.schernthaner@meduniwien.ac.at.
245    10
$a SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class / $c G. Schernthaner, H. Drexel, E. Moshkovich, B. Zilaitiene, E. Martinka, L. Czupryniak, T. Várkonyi, A. Janež, K. Ducena, K. Lalić, T. Tankova, M. Prázný, L. Smirčić Duvnjak, O. Sukhareva, H. Sourij,
520    9_
$a BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. EXPERT OPINION: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. CONCLUSION: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.
650    _2
$a kardiovaskulární nemoci $x epidemiologie $x etiologie $7 D002318
650    _2
$a komorbidita $7 D015897
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a prognóza $7 D011379
650    _2
$a glifloziny $x škodlivé účinky $7 D000077203
655    _2
$a časopisecké články $7 D016428
700    1_
$a Drexel, Heinz $u VIVIT-Institute, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. heinz.drexel@extern.insel.ch. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria. heinz.drexel@extern.insel.ch. Division of Angiology, Swiss Cardiovascular Center, University Hospital of Berne, Bern, Switzerland. heinz.drexel@extern.insel.ch. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein. heinz.drexel@extern.insel.ch. Drexel University College of Medicine, Philadelphia, PA, USA. heinz.drexel@extern.insel.ch.
700    1_
$a Moshkovich, Evgeny $u Unit of Endocrinology and Metabolism, Sapir Medical Center, Kfar-Saba, Israel.
700    1_
$a Zilaitiene, Birute $u Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
700    1_
$a Martinka, Emil $u National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.
700    1_
$a Czupryniak, Leszek $u Department of Diabetology and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
700    1_
$a Várkonyi, Tamás $u 1st Dept of Internal Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Janež, Andrej $u Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia.
700    1_
$a Ducena, Kristine $u Division of Endocrinology, Faculty of Internal Medicine, University of Latvia, Riga, Latvia.
700    1_
$a Lalić, Katarina $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Beograd, Serbia.
700    1_
$a Tankova, Tsvetalina $u Clinical Centre of Endocrinology, Medical University - Sofia, Sofia, Bulgaria.
700    1_
$a Prázný, Martin $u Diabetes Centre, Charles University and General Faculty Hospital, Prague, Czech Republic.
700    1_
$a Smirčić Duvnjak, Lea $u School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia.
700    1_
$a Sukhareva, Olga $u Endocrinology Research Centre, Moscow, Russian Federation.
700    1_
$a Sourij, Harald $u Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
773    0_
$w MED00006837 $t BMC endocrine disorders $x 1472-6823 $g Roč. 19, č. 1 (2019), s. 64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31208401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113101638 $b ABA008
999    __
$a ok $b bmc $g 1483019 $s 1083423
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 64 $e 20190617 $i 1472-6823 $m BMC endocrine disorders $n BMC Endocr Disord $x MED00006837
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace